The autoinjectors market was valued at USD 2.17 billion in 2023, growing at a CAGR of 20.65% during the forecast period from 2024 to 2030 to reach USD 6.69 billion by 2030. The demand for autoinjectors is witnessing growth due to the number of indications requiring immediate and emergency administration of interventional drugs such as anaphylaxis and multiple sclerosis, allows for self-administration of drugs, offers a safe alternative to conventional syringes, and the favorable reimbursement programs for these procedures.
Anaphylaxis is another indication that sets in rapidly and may even lead to death. It is a serious systemic hypersensitivity reaction that is usually rapid in onset and may cause death. It can be defined as a rapidly evolving, generalized, multi-system, allergic reaction. According to the data provided by the Asthma and Allergy Foundation of America 2023, allergies are the sixth most common cause of chronic illnesses in the US. It further mentioned that more than 50 million people in the US suffer from different types of allergies in the country each year. As these allergies can manifest into anaphylactic shocks, they require immediate administration of epinephrine injections, which are also being sold in prefilled autoinjector form by certain companies.
Furthermore, the added advantages associated with the autoinjectors such as virtually painless administration of medication, cost-effectiveness, reduced risk of needle stick accidents, and increased patient compliance in terms of helping people with needle phobia.
However, the availability of alternative products such as conventional needles and syringes in the market may restrain the growth of the autoinjectors market during the forecast period.
In the product segment of the autoinjectors market, the disposable autoinjectors category is estimated to amass a larger market share in the historic period. This can be attributed to their preferred use among end-users due to the presence of a built-in glass syringe which eliminated the need for the manual insertion of the glass syringe. These types of syringes prove to be useful for patients with visual impairments and reduced limb mobility.
Also, owing to the technological advancements in product development, there has been an increase in the number of reusable autoinjectors in the market. These autoinjectors allow for the replacement of the drug cartridges after the expiration of the shelf-life. Moreover, to keep up with the demand for smart technologies in the market, companies have also started offering smart reusable autoinjectors as well such as SmartPilot and Aria Smart Autoinjector, thereby projecting a fast growth period for this product category in the forecast period.
As per the data provided by the Migraine Research Foundation (2023), approximately 39 million people including both children and adult populations suffer from migraine in the country. It further stated that more than 4 million people experience chronic migraine episodes daily in the US. Migraine is an extremely debilitating neurological illness that leaves over 90% of sufferers in a compromised state unable to work or function normally during their migraine.
Furthermore, according to the National Multiple Sclerosis Society, United States, in 2022, it has been estimated that about one million people are currently living in the country with MS, which is twice the number of previous estimates. These indications among others can drastically affect the quality of life of patients and more so often require urgent administration of the therapeutic drug in events of sporadic onset of an episode.
Moreover, the US Food and Drug Administration (FDA) is a highly active regulatory body that focuses not only on the careful regulation of the approval processes of medical devices and pharmaceutical products but also engages extensively in educating patients and caregivers regarding new treatment methods, products, and even adversities related to them. This has resulted in the presence of a highly aware patient population in the country.
Additionally, the large presence of key market players in the country as well as the launch of new products in the country also provide favorable conditions for the growth of the Autoinjectors market in the region.
In August 2020, the US FDA approved Kesimpta® (as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is the first B-cell therapy that can be self-administered by patients via the Sensoready autoinjector pen.
Therefore, owing to the above-mentioned factors, the market for autoinjectors in the United States and North America is predicted to witness significant growth in the forecast period.
This product will be delivered within 2 business days.
Autoinjectors Market Dynamics:
The autoinjectors market is estimated to register significant growth in the forecast period on account of the growing need for emergency administration of therapeutic drugs. As per the data provided by the Multiple Sclerosis International Federation, Atlas of MS, 3rd Edition, in 2020, the estimates of the number of people living with MS worldwide increased to 2.8 million in 2020. The estimates presented a 30% increase from 2013 data. The 2020 global prevalence is 35.9 per 100,000 people. Multiple sclerosis (MS) is a debilitating indication that usually presents at a highly productive stage of life and can massively impact the quality of life of patients. Even though there is no specific cure for the indication at present for the treatment of MS, many therapies such as AVONEX Pens are available in the market that helps in controlling clinical exacerbations associated with MS.Anaphylaxis is another indication that sets in rapidly and may even lead to death. It is a serious systemic hypersensitivity reaction that is usually rapid in onset and may cause death. It can be defined as a rapidly evolving, generalized, multi-system, allergic reaction. According to the data provided by the Asthma and Allergy Foundation of America 2023, allergies are the sixth most common cause of chronic illnesses in the US. It further mentioned that more than 50 million people in the US suffer from different types of allergies in the country each year. As these allergies can manifest into anaphylactic shocks, they require immediate administration of epinephrine injections, which are also being sold in prefilled autoinjector form by certain companies.
Furthermore, the added advantages associated with the autoinjectors such as virtually painless administration of medication, cost-effectiveness, reduced risk of needle stick accidents, and increased patient compliance in terms of helping people with needle phobia.
However, the availability of alternative products such as conventional needles and syringes in the market may restrain the growth of the autoinjectors market during the forecast period.
Autoinjectors Market Segment Analysis:
Autoinjectors Market by Product Type (Disposable and Reusable), Type (Prefilled and Fillable), Portability (Handheld and Wearable), Indication (Rheumatoid Arthritis, Diabetes, Anaphylaxis, Multiple Sclerosis, and Others), End-User (Hospitals, Clinics, and Homecare Settings), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).In the product segment of the autoinjectors market, the disposable autoinjectors category is estimated to amass a larger market share in the historic period. This can be attributed to their preferred use among end-users due to the presence of a built-in glass syringe which eliminated the need for the manual insertion of the glass syringe. These types of syringes prove to be useful for patients with visual impairments and reduced limb mobility.
Also, owing to the technological advancements in product development, there has been an increase in the number of reusable autoinjectors in the market. These autoinjectors allow for the replacement of the drug cartridges after the expiration of the shelf-life. Moreover, to keep up with the demand for smart technologies in the market, companies have also started offering smart reusable autoinjectors as well such as SmartPilot and Aria Smart Autoinjector, thereby projecting a fast growth period for this product category in the forecast period.
North America is expected to dominate the Overall Autoinjectors Market:
Among all the regions, North America is expected to account for the largest share of the autoinjectors market. This can be attributed to the increasing cases of indications such as rheumatoid arthritis, migraine, MS, and anaphylaxis among others, the presence of a highly aware patient pool, as well as better healthcare access in the region.As per the data provided by the Migraine Research Foundation (2023), approximately 39 million people including both children and adult populations suffer from migraine in the country. It further stated that more than 4 million people experience chronic migraine episodes daily in the US. Migraine is an extremely debilitating neurological illness that leaves over 90% of sufferers in a compromised state unable to work or function normally during their migraine.
Furthermore, according to the National Multiple Sclerosis Society, United States, in 2022, it has been estimated that about one million people are currently living in the country with MS, which is twice the number of previous estimates. These indications among others can drastically affect the quality of life of patients and more so often require urgent administration of the therapeutic drug in events of sporadic onset of an episode.
Moreover, the US Food and Drug Administration (FDA) is a highly active regulatory body that focuses not only on the careful regulation of the approval processes of medical devices and pharmaceutical products but also engages extensively in educating patients and caregivers regarding new treatment methods, products, and even adversities related to them. This has resulted in the presence of a highly aware patient population in the country.
Additionally, the large presence of key market players in the country as well as the launch of new products in the country also provide favorable conditions for the growth of the Autoinjectors market in the region.
In August 2020, the US FDA approved Kesimpta® (as an injection for subcutaneous use for the treatment of relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. It is the first B-cell therapy that can be self-administered by patients via the Sensoready autoinjector pen.
Therefore, owing to the above-mentioned factors, the market for autoinjectors in the United States and North America is predicted to witness significant growth in the forecast period.
Autoinjectors Market Key Players:
Some of the key market players operating in the autoinjectors market include BD, Ysmoed AG, Sonceboz, Phillips-Medisize, Nemera, Novartis, Teva Pharmaceuticals, Amgen, GSK, Mylan Inc, Elcam Medical, Union Medico Injection Safety ApS, SHL Medical AG, Haselmeier, Owen Mumford Ltd, and others.Recent Developmental Activities in Autoinjectors Market:
- In May 2022, Phillips-Medisize, a Molex Company launched their Aria Smart Autoinjector Platform. This includes a small smart injectable device that features a reusable electronic drive unit and single-use disposable cassettes.
- In January 2020, Teva Pharmaceuticals received product approval from the US Food and Drug Administration for the autoinjector for the delivery of remanezumab, an anti-calcitonin gene-related peptide (anti-CGRP) approved for the prevention of migraine in adults.
- In October 2019, BD launched the BD Intevi 1mL two-step disposable autoinjector. This device combines an autoinjector and pre-fillable syringe in one integrated system.
Key Takeaways from the Autoinjectors Market Report Study
- Market size analysis for current market size (2023), and market forecast for 6 years (2024 to 2030)
- Top key product/services/technology developments, mergers, acquisitions, partnerships, and joint ventures happened for the last 3 years
- Key companies dominating the global autoinjectors market.
- Various opportunities available for the other competitor in the autoinjectors market space.
- What are the top-performing segments in 2023? How these segments will perform in 2030?
- Which are the top-performing regions and countries in the current autoinjectors market scenario?
- Which are the regions and countries where companies should have concentrated on opportunities for autoinjectors market growth in the coming future?
Target Audience who can be benefited from this Autoinjectors Market Report Study
- Autoinjectors products providers
- Research organizations and consulting companies
- Autoinjectors-related organization, association, forum, and other alliances
- Government and corporate offices
- Start-up companies, venture capitalists, and private equity firms
- Distributors and Traders dealing in autoinjectors
- Various End-Users who want to know more about the autoinjectors market and the latest technological developments in the autoinjectors market.
Frequently Asked Questions for Autoinjectors Market:
1. What are Autoinjectors?
An autoinjector device (AID) is a medical device that is employed in the administration of drugs majorly in emergencies. They help in the administration of drugs commonly via subcutaneous or intramuscular routes.2. What is the market for autoinjectors?
The autoinjectors market was valued at USD 2.17 billion in 2023, growing at a CAGR of 20.65% during the forecast period from 2024 to 2030 to reach USD 6.69 billion by 2030.3. What are the drivers for the autoinjectors market?
The major factors driving the demand for autoinjectors in the market are the rising prevalence of indications that require emergency administration of drugs such as multiple sclerosis and anaphylaxis, the flexibility of self-administration of drugs, and the advantages over conventional syringes, among other factors.4. What are the key players operating in the global autoinjectors market?
Some of the key market players operating in the autoinjectors market include BD, Ysmoed AG, Sonceboz, Phillips-Medisize, Nemera, Novartis, Teva Pharmaceuticals, Amgen, GSK, Mylan Inc, Elcam Medical, Union Medico Injection Safety ApS, SHL Medical AG, Haselmeier, Owen Mumford Ltd, and others.5. What region has the highest share in the autoinjectors market?
North America is expected to account for the highest revenue share in the autoinjectors market during the forecast period. Factors such as the presence of a highly-aware patient population in terms of device technology, better healthcare access along with the presence of a large patient population in the region are expected to be major influencing factors in the North American autoinjectors market.This product will be delivered within 2 business days.
Table of Contents
1. Autoinjectors Market Report Introduction
2. Autoinjectors Market Executive Summary
4. Regulatory Analysis
5. Autoinjectors Market Key Factors Analysis
6. Autoinjectors Market Porter’s Five Forces Analysis
7. Autoinjectors Market Assessment
8. Autoinjectors Market Company and Product Profiles
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- BD
- Ysmoed AG
- Sonceboz
- Phillips-Medisize, Nemera
- Novartis
- Teva Pharmaceuticals
- Amgen
- GSK
- Mylan Inc
- Elcam Medical
- Union Medico Injection Safety ApS
- SHL Medical AG
- Haselmeier
- Owen Mumford Ltd
